In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $325.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tazeen Ahmad has given his Buy rating due to a combination of factors including Alnylam Pharma’s promising launch of Amvuttra for ATTR-CM, which is showing early signs of success. The company’s strategy to position Amvuttra as the preferred first-line treatment is supported by its unique mechanism of action and favorable dosing schedule, which management believes will lead to significant market growth. Additionally, the large number of undiagnosed patients in the ATTR-CM market presents a substantial opportunity for expansion.
Another factor contributing to the Buy rating is the positive progress in payor negotiations, which are expected to facilitate the drug’s uptake. Furthermore, Alnylam’s pipeline, particularly the potential of nucresiran with its extended intellectual property and promising profile, adds to the company’s long-term growth prospects. The minimal impact from tariffs and stable interactions with the FDA further reinforce the positive outlook for Alnylam Pharma’s stock.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $280.00 price target.
ALNY’s price has also changed moderately for the past six months – from $287.360 to $230.930, which is a -19.64% drop .